Mounjaro Clinic in Spokane Valley

Weight regain can happen after stopping any weight loss medication if the habits that support progress are not in place. At ShillMed, we help patients develop sustainable nutrition, movement, and lifestyle strategies so they are better prepared for long-term success. The goal is to use medication as a bridge toward healthier routines, not as the only strategy. However, if you have type 2 diabetes, you may need to continue Mounjaro long-term to maintain blood sugar control. It is important to discuss this with your doctor.

Mounjaro is FDA-approved for type 2 diabetes, and it is also prescribed off-label in some cases for weight management under medical supervision. A provider can help determine whether it is appropriate based on your health history and treatment goals. At our clinic, we review your candidacy carefully before recommending any medication.Zepbound may be recommended for weight loss over Mounjaro. Visit our Zepbound page to learn more.

While semaglutide medications (like Ozempic and Wegovy) are single-target GLP-1 receptor agonists, Mounjaro and Zepbound (tirzepatide) are dual GIP and GLP-1 receptor agonists (sometimes called a "twincretin"). By targeting both the GIP and GLP-1 pathways simultaneously, Mounjaro acts on two key metabolic gut hormones to regulate appetite, enhance insulin secretion, and improve blood sugar control. Because these medications work through different pathways, individual patient responses, side effect profiles, and weight loss results can vary. The right choice depends on your specific health profile, medical history, tolerance, and overall treatment goals.

Good candidates are typically adults who may benefit from medically supervised weight loss and who have been evaluated for safety, side effects, and treatment goals. Your provider will consider factors such as blood sugar status, current medications, medical history, and previous weight loss attempts. We help patients determine whether GLP-1 therapy is appropriate for their situation.

Results vary depending on the individual, dose, adherence, nutrition habits, activity level, and starting health status. No medication can guarantee a specific amount of weight loss. At ShillMed, we focus on building a realistic, sustainable plan that supports steady progress and overall metabolic health.Clinical trials evaluating tirzepatide (the active ingredient in Mounjaro) demonstrate significant weight loss across different patient populations:In adults with Type 2 Diabetes (SURPASS Trials): In Mounjaro’s primary clinical trials—such as SURPASS-2—adults taking the highest dose (15 mg) lost an average of up to 11.2 kg (approx. 25 lbs / 11–13% of body weight) over 40 weeks, while also achieving significant reductions in blood sugar (A1C).In adults with Type 2 Diabetes and Obesity (SURMOUNT-2): In a 72-week trial specifically measuring weight management in adults with diabetes, mean weight loss was -12.8% (10 mg) and -14.7% (15 mg) compared to -3.2% with placebo, corresponding to an average loss of 29–33 lbs.In adults without Diabetes (SURMOUNT-1): In clinical studies evaluating tirzepatide for weight management in adults without diabetes, mean weight loss at 72 weeks reached -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) compared to -3.1% with placebo. Over 90% of participants on the 15 mg dose achieved ≥5% weight loss, and 36% achieved ≥25% weight loss.

Common side effects may include nausea, stomach discomfort, constipation, diarrhea, or reduced appetite, especially when treatment begins or doses change. Many of these symptoms can be minimized with proper dosing, nutrition strategies, and provider guidance. We monitor patients closely so adjustments can be made when needed. See a comparison between Ozempic and Mounjaro here.

Mounjaro and Zepbound contain the exact same active ingredient, tirzepatide. The primary difference is their FDA-approved use. Mounjaro is approved for treating type 2 diabetes, while Zepbound is approved for chronic weight management and sleep apnea in eligible adults.

Yes, this GLP-1 is FDA-approved. You can view one study here.